Evolution of patients with Sézary syndrome after mogamulizumab discontinuation for any cause except progression: a multicenter retrospective study (Moga-stop study)

Archive ouverte

Tzoumpa, Sofia | Ingen-Housz-Oro, Saskia | de Masson, Adèle | Pham-Ledard, Anne | El Aarbaoui, Tarik | Dereure, Olivier | Quereux, Gaëlle | Faiz, Sarah | de Vicq de Cumptich, Marine | Ram-Wolff, Caroline | Janela-Lapert, Raphaël | Guenova, Emmanuella | Lheure, Coralie | Le Corre, Yannick | Adamski, Henri | Blanchard, Maël | Bonnet, Nathalie | Amatore, Florent | Grange, Florent | Troin, Laura | Bagot, Martine | Beylot-Barry, Marie

Edité par CCSD ; Wiley -

International audience. The results of this study suggest that a progressive discontinuation of mogamulizumab should be considered once response is obtained in Sezary syndrome patients, even after a treatment of short-duration. This may possibly minimize the risk of adverse effects, costs, and resistance to mogamulizumab. Additionally, our study emphasizes that mogamulizumab rechallenge should be encouraged as first-choice for relapsing patients. . No abstract available

Consulter en ligne

Suggestions

Du même auteur

Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study

Archive ouverte | Bozonnat, Alizée | CCSD

International audience. Background: Sézary syndrome is an extremely rare and fatal cutaneous T-cell lymphoma (CTCL). Mogamulizumab, an anti-CCR4 monoclonal antibody, has recently been associated with increased progr...

Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study

Archive ouverte | de Masson, Adèle | CCSD

International audience

HAVCR2 mutations are associated with severe hemophagocytic syndrome in subcutaneous panniculitis-like T-cell lymphoma

Archive ouverte | Sonigo, Gabrielle | CCSD

International audience

Chargement des enrichissements...